Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Curigliano et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69d832dbf4e559c61eae2bc4 — DOI: https://doi.org/10.1158/1078-0432.ccr-20-4746

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Cancer phase I clinical trials: efficient dose escalation with overdose control· 1998 · 619 citations
2. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity· 2010 · 2,054 citations
3. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,254 citations
4. First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.